Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.
Our annual report takes a look at pharma’s current investment in drug development, which this year demonstrates a focus on five important therapeutic areas of interest—Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids.